Quick Take: BGI Genomics Partners With Traditional Chinese Medicine Supplier

Photo: Visual China
Photo: Visual China

Chinese genome giant BGI Genomics Co. Ltd. has expanded into a new business: helping to standardize and modernize traditional Chinese medicine (TCM).

BGI has agreed to set up a joint venture with Kangmei Pharmaceutical Co. Ltd., a TCM developer that cultivates several herb plantations in China, the companies announced Friday.

Kangmei Pharma will contribute 95% of the $7.5 million project’s funding, while BGI will provide devices and technology. A Kangmei representative told Caixin that the drugmaker wants to grasp a better understanding of herbs to control TCM quality and improve its efficacy.

You've accessed an article available only to subscribers
Try 4 weeks for $0.99
Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.